The Intersexual Differences of Sexual Functions and Prolactine Levels in Schizophrenia Patients Under Antipsychotic Medication

DOGU B., KOCABIYIK A., KARSON F., Citak S., Incesu C.

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.48, pp.35-38, 2011 (Peer-Reviewed Journal) identifier

  • Publication Type: Article / Article
  • Volume: 48
  • Publication Date: 2011
  • Doi Number: 10.4274/npa.y6076
  • Journal Indexes: Science Citation Index Expanded, Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.35-38


This study was set out to research the inter-sexual differences in the relation between prolactin levels and sexual dysfunction, independently from the type and dosage of anti-psychotic medicine used in schizophrenia patients treated at the outpatient treatment unit of Bakirkoy State Mental Hospital. The study included a total of 120 patients, 63 females and 57 males, all diagnosed with schizophrenia but in remission according to the DSM-IV diagnostic criteria. Prolactin levels in all patients were measured. The Brief Psychiatric Rating Scale (BPRS) and the Calgary Depression Scale for Schizophrenia were used to determine if the patients within the study were in remission in terms of schizophrenic and depressive symptoms as well as the Golombok Rust Inventory of Sexual Satisfaction (GRISS) - to assess sexual dysfunction. Moreover, the patients were required to fill out a socio-demographic survey form designed in order to evaluate the patients' subjective view of their sexual life and to determine the type of drugs used by the patient, in addition to other data. The study concluded that antipsychotic treatment of schizophrenia led to a greater increase in prolactin levels in female patients than in male ones and caused development of amenorrhoea and galactrorrhoea, but it did not influence sexual functions significantly, whereas it caused hyperprolactinemia in male patients less and had a negative impact on their sexual function; moreover, increase in prolactin levels led to decreased sexual desire in both genders. In conclusion, there is a necessity to focus more on decreased sexual desire in schizophrenia patients receiving anti-psychotic treatments and to explore sexual dysfunction in detail. Further research studies are needed regarding the mechanisms by which anti-psychotic treatments lead to hyperprolactinemia, and how hyperprolactinemia causes sexual side effects. (Archives of Neuropsychiatry 2011; 48 Supplement 1: 35-8)